Phase II study of bevacizumab in combination with cetuximab plus irinotecan in irinotecan-refractory colorectal cancer (CRC) patients who have progressed on a bevacizumab-containing regimen (The BOND 2.5 Study)

被引：0
|
作者：
Segal, N. H. [1 ]
Reidy-Lagunes, D. [1 ]
Capanu, M. [1 ]
Kemeny, N. [1 ]
Chung, K. [1 ]
Kelsen, D. [1 ]
Hollywood, E. [1 ]
Goodman-Davis, N. [1 ]
Saltz, L. B. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4087
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Phase II study of S-1-based sequential combination chemotherapy including oxaliplatin plus bevacizumab and irinotecan with or without cetuximab for metastatic colorectal cancer: the SOBIC trial
    Nakamoto, Yoshihiko
    Noda, Masafumi
    Mikami, Ryuichi
    Tokunaga, Yukihiko
    Okumoto, Tatsuo
    Kawamura, Takashi
    Fujiwara, Hidetoshi
    Doi, Sadayuki
    Tomita, Naohiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (07) : 1285 - 1290
  • [32] Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: Final results from a randomised phase ii study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study)
    Ducreux, M.
    Adenis, A.
    Pignon, J. -P.
    Francois, E.
    Chauffert, B.
    Ichante, J. L.
    Boucher, E.
    Ychou, M.
    Pierga, J. -Y.
    Montoto-Grillot, C.
    Conroy, T.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1236 - 1245
  • [33] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in patients with metastatic colorectal cancer (mCRC)
    Garcia Alfonso, P.
    Chaves, M.
    Munoz Martin, A.
    Salud Salvia, A.
    Vilchez, R.
    Yuste, A.
    Gravalos Castro, C.
    Queralt Merino, B.
    Gonzalez Flores, E.
    Lopez Ladron, A.
    Losa, F.
    Oltra Ferrando, A.
    Gomez Reina, M. J.
    Campos, J. M.
    Aranda, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [34] PHASE II STUDY TO EVALUATE EFFICACY AND SAFETY OF IRINOTECAN, CAPECITABINE AND BEVACIZUMAB IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Garcia Alfonso, Pilar
    Chaves, Manuel
    Munoz, Andres
    Salud, Antonieta
    Garcia-Giron, Carlos
    Gravalos, Cristina
    Massuti, Bartomeu
    Gonzalez-Flores, Encarnacion
    Queralt, Bernardo
    Lopez-Ladron, Amelia
    Losa, Ferran
    Oltra, Amparo
    Jose Gomez, Ma
    Manuel Campos, J.
    Aranda, Enrique
    ANNALS OF ONCOLOGY, 2012, 23 : 103 - 104
  • [35] Phase II study to evaluate efficacy and safety of irinotecan, capecitabine, and bevacizumab in metastatic colorectal cancer (mCRC) patients
    Garcia Alfonso, Pilar
    Chaves-Conde, Manuel
    Munoz, Andres
    Salud, Antonia
    Garcia-Giron, Carlos
    Gravalos Castro, Cristina
    Massuti, Bartomeu
    Gonzalez Flores, Encarnacion
    Queralt, Bernardo
    Lopez Ladron, Amelia
    Losa, Ferran
    Oltra Ferrando, Amparo
    Gomez Reina, Maria Jose
    Garcia-Carbonero, Rocio
    Garcia-Escobar, Ignacio
    Aranda, Enrique
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [36] Phase II study of capecitabine, irinotecan (CAPIRI) plus bevacizumab in chemotherapy naive stage IV colorectal cancer, results in 120 patients
    Fonseca, P.
    Vieitez, J. M.
    Berros, J. P.
    Crespo, G.
    Fernandez de Sanmamed, M.
    Muriel, C.
    Izquierdo, M.
    Pardo, P.
    Lacave, A. J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 337 - 337
  • [37] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Yuki, S.
    Shitara, K.
    Yoshida, M.
    Takahari, D.
    Utsunomiya, S.
    Yokota, T.
    Sato, Y.
    Tajika, M.
    Muro, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [38] A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
    Suenaga, Mitsukuni
    Mizunuma, Nobuyuki
    Matsusaka, Satoshi
    Shinozaki, Eiji
    Ozaka, Masato
    Ogura, Mariko
    Chin, Keisho
    Yamaguchi, Toshiharu
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 1653 - 1662
  • [39] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Kohei Shitara
    Satoshi Yuki
    Motoki Yoshida
    Daisuke Takahari
    Setsuo Utsunomiya
    Tomoya Yokota
    Yozo Sato
    Yoshitaka Inaba
    Masahiro Tajika
    Hiroki Kawai
    Hidekazu Yamaura
    Mina Kato
    Kentaro Yamazaki
    Yoshito Komatsu
    Kei Muro
    Investigational New Drugs, 2012, 30 : 787 - 793
  • [40] Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines
    Shitara, Kohei
    Yuki, Satoshi
    Yoshida, Motoki
    Takahari, Daisuke
    Utsunomiya, Setsuo
    Yokota, Tomoya
    Sato, Yozo
    Inaba, Yoshitaka
    Tajika, Masahiro
    Kawai, Hiroki
    Yamaura, Hidekazu
    Kato, Mina
    Yamazaki, Kentaro
    Komatsu, Yoshito
    Muro, Kei
    INVESTIGATIONAL NEW DRUGS, 2012, 30 (02) : 787 - 793
12345